Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Paola Parra RamírezPatricia Martín Rojas-MarcosMiguel Paja FanoMargarita González-BoillosEider Pascual-CorralesAna María García CanoJorge Gabriel Ruiz-SanchezAlmudena Vicente DelgadoEmilia Gómez HoyosRui FerreiraIñigo García SanzMònica Recasens SalaRebeca Barahona San MillanMaría José Picón CésarPatricia Díaz GuardiolaCarolina M PerdomoLaura Manjón-MiguélezÁngel Rebollo RománCristina Robles LázaroManuel Morales-RuizMaría CalatayudSimone Andree Furio CollaoDiego MenesesMiguel Antonio Sampedro-NuñezElena Mena RibasAlicia Sanmartín SánchezCesar Gonzalvo DiazCristina LamasRaquel Guerrero-VázquezMaría Del Castillo TousJoaquín Serrano GotarredonaTheodora Michalopoulou AlevrasSusana Tenés RodrigoRicardo Roa ChamorroFernando Jaen AguilaEva María Moya MateoFelicia A HanzuMarta Araujo-CastroPublished in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2024)
Cardiovascular, renal, and metabolic events were comparable in MRA patients with unsuppressed and suppressed renin. Effective surgical treatment of PA was associated with a decreased incidence of new cardiovascular events when compared to MRA therapy.
Keyphrases
- cardiovascular events
- end stage renal disease
- coronary artery disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- cardiovascular disease
- contrast enhanced
- prognostic factors
- peritoneal dialysis
- risk factors
- angiotensin converting enzyme
- type diabetes
- magnetic resonance imaging
- patient reported outcomes
- magnetic resonance
- bone marrow
- patient reported
- mesenchymal stem cells
- angiotensin ii